ImpriMed
AI-driven personalized medicine for veterinary and human cancer care
Healthcare & Biotech
AI, Robotics & Automation
Vision
ImpriMed is transforming both veterinary and human oncology with its cutting-edge AI-driven precision medicine approach. ImpriMed's innovative AI models leverage live cancer cell analytics to enable oncologists to make precise, data-driven treatment decisions tailored to individual patients. With proven success in over 10,000 cases in dogs and cats, the company is now expanding into human cancer treatment. Additionally, the live-cell-based drug efficacy assessment platform offers pharmaceutical companies an invaluable tool to pretest drug compounds on their target patients' live cells, enhancing clinical trial success rates and streamlining market entry.
Sub-Industries
Veterinary Oncology
AI-driven Cancer Treatment
Pet Health Biotechnology
Testimonial
Related Companies
Haply
Human interface layer for Physical AI, enabling robots to learn directly from human demonstration
Montreal, Canada
SymbyAI
AI co-pilot that automatically audits, replicates, and reviews scientific papers in minutes
Austin, TX, USA
KindBio
The future of organ replacement
Salem, NH, USA
The Embryo Corporation
Scalable embryo gene editing to build the next generation of animal life
Austin, TX, USA
Syncere
Ambient robotics for the home
Palo Alto, California, USA
Paterna Biosciecnes
In vitro gematogenesis platform company to address male and female intertility
Salt Lake City, UT, USA
Terminus Inudstrials
Reshoring and Automating Defense Grade Large Power Transformer Manufacturing
Austin, Texas, USA
